NEW YORK ─ In the early days of the SARS-CoV-2 pandemic, many observers saw substantial commercial and clinical potential for serology tests for the virus.
Yet, despite this initial enthusiasm, these assays have struggled to carve out a significant market, hampered by concerns about test performance and the lack of a clear role in clinical decision-making.
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
